On July 28, Merck rose 3.12% in regular trading, trading at 133.55 USD/share, with turnover of $251 million. The gain was driven by a broad pharma sector rally and a notable target price upgrade from Barclays.

On the sector front, GlaxoSmithKline surged nearly 7% after reporting Q2 adjusted earnings per share of 50.5 pence, significantly above the consensus estimate of 46.8 pence, lifting sentiment across the pharmaceutical space. Multiple large-cap pharma names advanced, with Pfizer up over 3%, AbbVie up nearly 4%, and Amgen up over 5%.

Separately, Barclays raised its price target on Merck to $150 from $140 while maintaining an Overweight rating, marking one of several recent institutional upgrades. JPMorgan and BMO also recently lifted their targets to $140 and $142, respectively. On the fundamental side, Merck has accumulated a string of positive catalysts including Keytruda meeting the primary endpoint in a Phase 3 endometrial cancer trial, FDA approval of Lipfendra as the first oral PCSK9 inhibitor, and voluntary licensing agreements with seven generic manufacturers to advance global access to its investigational HIV drug alimatravir.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)